VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization
VICTORY-HF
1 other identifier
interventional
891
2 countries
9
Brief Summary
The clinic visits (intervention) will continue for 90 days, which represents the follow-up period for the primary medication and health status outcomes. The co-primary clinical outcomes will be obtained at 180 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable heart-failure
Started Jan 2023
Typical duration for not_applicable heart-failure
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 31, 2019
CompletedStudy Start
First participant enrolled
January 23, 2023
CompletedFirst Posted
Study publicly available on registry
February 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedDecember 31, 2024
December 1, 2024
2.9 years
August 31, 2019
December 27, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Primary "Hierarchical" Composite Outcome of:
1. Target dose of BB, ARNI or ACEi/ARB, MRA, and SGLT2i at 90 days 2. GDMT intensification at 30 days, defined as (a) initiation or up-titration of beta-blocker; (b) switch from another beta blocker to carvedilol, bisoprolol, or extended-release metoprolol; (c) initiation or up-titration of ACEi/ARB or ARNI; (d) switch from ACEi/ARB to ARNI; (e) initiation or up-titration of MRA; or (f) initiation of SGLT2i 3. Change in health status, as measured by the KCCQ-12 summary score at 90 days PLEASE NOTE: THESE ARE "HIERACHIAL OUTCOMES"
30 and 90 days
Co-primary "Hierarchical" Composite Outcome of:
1. All cause death at 180 days 2. HF hospitalization at 180 days 3. All-cause ED visit at 180 days 4. Change in KCCQ-12 summary score at 90 days PLEASE NOTE: THESE ARE "HIERACHIAL OUTCOMES"
90 and 180 days
Secondary Outcomes (4)
GDMT use
90 days
Clinical Outcomes
90 days and 180 days
Healthcare utilization
90 days and 180 days
Healthcare utilization
90 days and 180 days
Study Arms (2)
Virtual HF care
EXPERIMENTALPatients will receive virtual HF care to optimize medical therapies
Routine HF care
OTHERParticipants will receive routine HF care
Interventions
Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
Eligibility Criteria
You may qualify if:
- Adult patients ≥ 18 years old who:
- Are being discharged after hospitalization or urgent visit for HF as
- a primary diagnosis or
- significant complication (prolonging length of stay) of another diagnosis OR Have been referred for an initial consult at a cardiology clinic within 1 week of hospitalization or urgent visit for HF as a primary or secondary diagnosis, as described above.
- Have left ventricular ejection fraction (LVEF) \< 50% within the preceding 3 months.
- Have NT-proBNP of \> 900 pg/ml during hospital admission or within 7 days after discharge from the ED
- Have a mailing address for patient or caregiver
- Provide verbal consent
You may not qualify if:
- Died or left hospital before medically advised hospital discharge
- Unable to self-assess or communicate symptoms (e.g. clinically evident dementia)
- Unable to engage with digital health technology or follow up
- Severe valve disease
- Recipient of or on waiting list for LVAD or cardiac transplant
- Complex congenital heart disease, hypertrophic obstructive cardiomyopathy, or amyloid cardiomyopathy
- Severe lung disease with symptoms on minimal exertion, forced expiratory volume during 1 second (FEV1) \< 1 litre, severe pulmonary hypertension with RVSP \> 60 mm Hg, or on home oxygen
- Severe kidney disease (persistent eGFR \< 30 mL/min/1.73m2)
- Active malignancy
- Receiving palliative care or expected life expectancy \< 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Population Health Research Institutelead
- Hamilton Health Sciences Corporationcollaborator
- McMaster Universitycollaborator
Study Sites (9)
St. Joseph's Healthcare Hamilton
Hamilton, Onatrio, L8N 4A6, Canada
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2, Canada
Juravinski Hospital Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
Unity Health Toronto
Toronto, Ontario, Canada
Fattouma Bourguiba Hospital
Monastir, Tunisia
Hedi Chaker Hospital
Sfax, Tunisia
Sahloul Hospital
Sousse, Tunisia
Military Hospital
Tunis, Tunisia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Harriette Van Spall, MD
McMaster University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Medicine, Division of Cardiology, McMaster University, Population Health Research Institute
Study Record Dates
First Submitted
August 31, 2019
First Posted
February 13, 2023
Study Start
January 23, 2023
Primary Completion
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Last Updated
December 31, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share